Immunoassay; biospecific binding assay; materials therefor (G01N33/53)

Method for prediction of infectious complication of atopic dermatitis in children

Treating infantile and child's active atopic dermatitis is combined with determining the child's blood serum complement component C3, interleukin 6 and interleukin 10 concentrations. If the complement component C3 concentration is less than 0.8 mg/ml, while the interleukin 6 concentration is more than 20.9 ng/ml and the interleukin 10 concentration is more than 5.6 ng/ml, the developing infectious complication of atopic dermatitis in a child is predicted.

Method for prediction of risk of severe neonatal nervous system involvement in new-borns of various gestations

Invention refers to medicine, namely to neonatology and child neurology, and can be used to predict a risk of a neonatal central nervous system (CNS) involvement in new-borns of various gestations. Substance of the method: vascular endothelial growth factor and blood serum neurospecific enolase are measured. That is followed by calculating a probability of the severe central nervous system involvement p by formula: p=1/(1+e-F), wherein e is a base of natural logarithm = 2.718; F is a discriminant function calculated by formula: F=0.0235·VEGF-4.5·NSE-2.46, wherein VEGF is the blood serum vascular endothelial growth factor; NSE is the blood serum neurospecific enolase. If p is 0.5 or more, a low risk is predicted, and if p is less than 0.5, a high risk of the severe CNS involvement is predicted.

Method for preparing immunosorbent for diagnosing herpes simplex type i

Invention represents a method for preparing an immunosorbent for diagnosing herpes simplex type I virus involving preparing a polymer solid-phase carrier adsorbing a herpes type I virus antigen, aqueous 20% polyethylene glycol (PEG-20), adsorbing on the carrier in 0.2M carbonate-bicarbonate buffer at pH 9.6 of the lysate high-purity herpes type 1 virus antigen prepared of the herpes simplex type I virus strain - ATCC VR-539, washing, lyophilisation, incubation of the sorbed antigens with a blocking solution. Using the natural lysate high-purity herpes type I virus antigen ATCC-VR-539 enables providing considerably higher analysis sensitivity, tris-based blocking system ensures neutralising the undesired non-specified reactions. Besides, using the invention leads to better conditions of the agent activity on the surface of the solid-phase carrier, reducing the agent consumption.

Method for prediction of developing psychic deadaptation

Object is handled by measuring the immunological values in peripheral blood of persons being tested; if observing the content of CD72+ B-lymphocytes of 7% or less, the content of lymphocytes with late activation markers HLADR of 14% or less, the concentration of serum IgA of 1.96 g/l or less, the developing psychic deadaptation at the stage of the psychic adaptation state is predicted.

Vaccines and vaccine ingredients for microbial cell inhibition

Invention refers to biochemistry, particularly to a recovered polypeptide which is a biological target for methane-producing cell inhibition, as well as to a recovered polynucleotide which codes this polypeptide. There are disclosed expression vector and cloning vector containing this polynucleotide, and host cells containing the above expression vector. There are described conjugated molecules or fused molecule for methane-producing cell inhibition, as well as antibody or its functional fragment which binds to the above polypeptide. The invention also covers a pharmaceutical composition and methods for inhibiting and identifying the methane-producing cell with the use of the above conjugated molecule or fused molecule and the antibody or its fragment.

Method for prediction of developing haematogenous metastases following combined treatment of kidney cancer

Predicting developing haematogenous metastases following combined treatment of kidney cancer precedes determining the NF-kB p50, HIF-1α expression in the tumour tissue and the concentration of the vascular endothelial growth factor VEGF. Discriminant functions Y1, Y2 are calculated by equations: Y1=-3.2+0.026·X1+0.03·X2-0.02·X3+0.34·X4+0.3·X5; Y2=-33.3-0.01·X1+0.11-X2-1.2·X3+1.57·X4+1.8·X5, wherein X1 is the total proteasome activity ·10-3 IU/mg of protein; X2 is the concentration of VEGF, pg/mg of protein; X3 is HIF-1 expression, standard unit/mg of protein in a well; X4 is NF-kB p50 expression, standard unit/mg of protein in a well. If observing Y1>Y2, the absence of the haematogenous metastases is predicted, while Y1<Y2 enables predicting developing the haematogenous metastases.

Biological microchip for detection and multiparameter analysis of anticholeraic antibodies

What is presented is a biological microchip for the detection and multiparameter analysis of anticholeraic antibodies in human blood serum containing a massive of V. cholerae O-antigens discretely applied and immobilised on a carrier surface, and a cholera toxin grouped separately.

Immunological test for determining autoantibodies against testicular antigens

Present invention refers to an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammatory genital disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies.

Biological sensor and method of creation of biological sensors

Biological sensor is described, as well as the method of creation of a biological sensor using thin films based on grapheme, graphene oxide or single-walled or multi-walled carbon nanotubes. The biological sensor comprises a substrate, a metal film on the surface of which the intermediate bonding layer is applied, made of a thin film of graphene or a thin film of graphene oxide or a thin film of carbon nanotubes. On the surface of the intermediate bonding layer the biospecific layer is adsorbed conformally and uniformly. The biospecific layer can be used as a layer of molecules of the binding partner of the analyte or a layer of a complex of biological molecules capable of interacting chemically with the molecules of the binding partner and forming a complex with them. Also the biospecific layer can be used as the hydrogel layer, on which the binding partner molecule and/or complex of binding partner molecules and biological molecules is deposited, which can form a chemical bond with the binding partner molecules. The described method of obtaining the biological sensor comprises the stages of applying a metal film, an intermediate bonding layer and a biospecific layer.

Method of lifetime diagnostics of latent course of infectious anaemia in chickens

Method of lifetime diagnostics of latent course of infectious anaemia in chickens comprises morphological evaluation of blood smears and bone marrow punctate of sick chickens. In blood smears and bone marrow punctate the virus-induced apoptotic bodies are identified, and in case of presence in the field of view of 3-5 and more apoptotic cells the chicken infectious anaemia is diagnosed.

Qualitative differential instant diagnostic technique for parotid gland growths shown by patient's oral fluid biomarkers

Technique involves performing a patient's oral fluid analysis with the patient's oral fluid sampled prior to or not less than 30 minutes following meals, centrifuging the patient's oral fluid at 3000 rpm for 15 minutes, diluting the oral fluid with physiological solution in a ratio of 1:100 and centrifuging once again at 3000 rpm for 15 minutes, placing the prepared patient's oral fluid material into a tray and performing a standard enzyme immunoassay of monoclonal antibodies; that is followed by the findings analysis; the oral fluid is sampled from the patient for the purpose of qualitative differential instant diagnosis of the parotid gland growths as shown by the oral fluid biomarkers; the biomarker is matrix metal metalloproteinase 8 (MMP 8) to be measured in the patient's oral fluid; the qualitative content of the biomarker MMP 8 of the clinical reference oral fluid biomarker is 23.85-39.65 ng/ml, and if MMP 8 is found in an amount of 611.32-792.00 ng/ml, the parotid gland adenoma is diagnosed, and if MMP 8 is found in an amount of 496.86-570.33 ng/ml, the parotid gland cancer is diagnosed; matrix metalloproteinase 9 (MMP 9) is measured in the patient's oral fluid; the clinical reference oral fluid biomarker makes 108.14-180.47 ng/ml; if MMP9 is found in an amount of 326.43-458.23 ng/ml, the parotid gland adenoma is diagnosed, and if MMP9 making 782.13-906.60 ng/ml enables diagnosing the parotid gland cancer; the derived values of the patient's oral fluid biomarkers are used to predict a therapeutic approach to the patient.

Diagnostic technique for spontaneous secondary immune deficiency in children with primary peritonitis

Sampled venous blood is examined for relative activated classical monocyte with the phenotype CD14bright CD16-HLA-DR+ of total monocytes with the phenotype CD14bright by multicolour flow cytometry, and if the derived value is more than 68.8%, spontaneous secondary immune deficiency is diagnosed.

Method for prediction of developing threshold retinopathy of prematurity in infants having no ophthalmic signs of disease

Invention represents method for prediction of threshold retinopathy of prematurity in infants having no ophthalmic signs of the disease characterised by the fact that blood serum is analysed for vascular endothelial growth factor (VEGF) up to the 33rd week of gestation; if the VEGF level is 1300 pg/ml or more, developing threshold retinopathy of prematurity is predicted.

Method for determining functional activity of ionised calcium in human blood serum

Invention can be used for determining functional activity of ionised calcium (FAI Ca2+) in human blood serum. The method for determining FAI Ca2+ is based on conducting a bovine erythrocyte lysis reaction in 10% human blood serum at temperature 37°C for 10 min in the presence of 0.55 mM ethylene glycol tetraacetic acid in a buffer for 10 min. An incubation is followed by determining a degree of inhibition of erythrocyte lysis; if observing a complement activity inhibition of less than 30%, a high functional activity of ionised calcium in a human body is stated; the inhibition of 31% to 70% shows the normal activity, and the inhibition of more than 71% - the low activity.

Diagnostic technique for external genital endometriosis

Invention represents a diagnostic technique for external genital endometriosis involving blood serum analysis, differing by the fact that the blood serum is analysed for high-density lipoproteins, and if the derived value is 0.77 mmole/l and higher, external genital endometriosis is diagnosed.

Method for titration of group abo antibodies

Titration of natural antibodies is ensured by introducing 0.8% test erythrocyte suspension 50 mcl and one of the prepared dilutions of blood serums 25 mcl into each column of a neutral gel card. The prepared mixtures are incubated for 20-25 minutes at 21-23°C. That is followed by centrifugation and titration in limiting dilution to detect visible agglutination in the thickness of the column of the gel card. Titration of complete immune antibodies is ensured by using blood serum 100-200 mcl diluted four times. The serum diluted 1:4 is heated for 10 minutes at temperature 70°. The following dilutions of the heated serum 1:4 are prepared. Further, 0.8% test erythrocyte suspension 50 mcl and one of the prepared dilutions 25 mcl are introduced into each column of the neutral gel card. The prepared mixtures are incubated for 20-25 minutes at temperature 21-23°C, centrifuged and titred. Titration of incomplete immune antibodies is ensured by using blood serum 100-200 mcl diluted four times. The diluted blood serum is heated for 10 minutes at temperature 70°C. The following dilutions of the heated serum 1:4 are prepared. Further, 0.8% test erythrocyte suspension 50 mcl and one of the prepared dilutions 25 mcl are introduced into each column of the gel card with the reagent Coombs. The prepared mixtures are incubated with the gel card or Coombs cards left for 20-25 minutes at temperature 37°C. Thereafter, the gel card or Coombs cards are centrifuged, and the examined antibodies are titred in limiting dilution to detect visible agglutination in the thickness of the column of the gel card.

Diagnostic technique for autoimmune disorders of gastrointestinal vegetative structures

Autoimmune disorder of gastrointestinal vegetative structures are diagnosed by examining patient's blood serum. The blood serum sample is examined for neuronal acetylcholine receptor α3-subunit (ACR-α3) and gonadolibarin releasing hormone (GnRH) antibodies by enzyme-linked immunosorbent assay (ELISA) as shown by a reaction to an extracellular portion of neuronal ACR α3-subunit and releasing hormon GnRH, while the ACR-α3 and GnRH levels are determined by straining using tetramethyl benzidine as a chromogene. An optical light absorption is determined by an ELISA analyser at wave length 450 nm in optical density (OD) units. If observing an increase of the ACR-α3 antibodies of more than 0.24 OD, and a decrease of the GnRH antibodies of less than 0.25 OD up to the full absence in relation to a reference, the autoimmune disorder of the peripheral vegetative nervous system at the level of gastrointestinal parasympathetic intramural ganglia and microganglia is diagnosed; if the GnRH antibody level is more than 0.25 OD, and the ACR-α3 antibody level is less than 0.24 up to the full absence, the autoimmune disorder of metasympathetic gastrointestinal intramural ganglia and microganglia is diagnosed.

Device and method of detecting urine test strips damaged by moisture

Invention relates to medicine, and describes method of detecting moisture-sensitive reagents, damaged by water, where said reagents are brought in contact with water-containing sample with further detection of analysed substance in sample by its reaction with said water-sensitive reagents, and said method includes: (a) measurement of light reflection with wavelength, characteristic of products of said reaction of said moisture-sensitive reagents with analysed substance in two set time points after contact of said reagents with said sample; (b) measurement in the same time points of light reflection with wavelength, characteristic for reference infrared dye, and said dye is combined with said water-sensitive reagents and has characteristic wavelength, different from wavelength, measured in i. (a), by, at least, 120 nm; (c) calculation of ratio of indices of reflection, measured at wavelengths in accordance with ii. (a) and (b), and conclusion about the fact that reagents have lower than expected activity and are damaged by humidity, on the basis of difference in said ratio for said two set time points.

Method for interferon-gamma producing t-lymphocyte test in chronic lymphatic leukaemia

Invention refers to medicine, namely to a method for interferon-γ producing T-lymphocyte test in chronic lymphatic leukaemia. Substance of the method consists in the fact that intracellular transport is inhibited by brefeldin A in a cell culture and immediately treated with fluorescein isothiocyanate labelled anti-CD3 antibodies; that is followed by stimulation of interferon-γ synthesis, fixation, permeabilisation, dyeing with phycoerythrin-labelled anti-interferon-γ monoclonal antibodies and cytometry; a matching of the fluorescent label of a CD3-marker in the cell culture and that determined by the reference method is witnessed.

Method of differential morphometric diagnostics of erythrodermal form of mycosis fungoides and syndrome of skin pseudolymphoma by relative volume of epidermis and mitotic index of epidermal cells

To perform differential morphometric diagnostics of an erythrodermal form of mycosis fungoides and the syndrome of skin pseudolymphom performed are: histological analysis of the affected skin biopsy samples by a method of light microscopy, immunodifferentiation of infiltrate cells, additional morphometric analysis of basal keratinocytes in histological preparations of the affected skin biopsy samples. In case of the similar histological picture, described in case of erythrodermal form of mycosis fungoides and the syndrome of skin pseudolymphoma such as acanthosis, hyperkeratosis, parakeratosis, oedema and vasodilatation of the derma, lymphohistiocytic infiltrates, located in the upper third of the derma, similar immunophenotype of the infiltrate cells in case of erythrodermal form of mycosis fungoides and the syndrome of skin pseudolymphoma, represented by CD2+, CD3+, CD4+, CD5+, CD43+, CD45RO+ lymphocytes, morphometric analysis of all epidermis cells is performed. After that, the relative volume of epidermis and mitotic index of the epidermal cells are calculated. In case of increase of the relative volume of the epidermis by 2.2 and more times in comparison with the normal skin and an increase of the mitotic index of the epidermal cells by 2.7 times and more in comparison with the normal skin, erythrodermal form of mycosis fungoides is diagnosed, and in case of the unchanged relative volume of the epidermis and the mitotic index of the epidermal cells in comparison with the normal skin, the syndrome of skin pseudolymphoma is diagnosed.

Method of predicting retardation of intrauterine foetus development

Invention relates to medicine, namely to obstetrics and gynaecology, and can be used for the prediction of retardation of intrauterine foetus development. For this purpose a relative content of CD3+CD16+56+-lymphocytes, a level of C3-component of the complement and the soluble receptor of tumour necrosis factor (sTNF-R) are determined in a woman's venous blood at early terms of pregnancy. The prognostic index (PI) is calculated by formula: PI=-0.8911X1-0.0321X2-2.3669X3+11.0779, where X1 is the relative content of CD3+CD16+56+-lymphocytes, %; X2 is the concentration of C3-component of the complement, mg/dl; X3 is the concentration of sTNF-R, ng/ml. If PI<0 retardation of intrauterine foetus growth in the second half of pregnancy is predicted, and if PI>0, a conclusion about a low risk of development of the said pathologic condition is made.

Method of predicting course of bacterial purulent meningitis in children

Presence of CD31 and S100 positive cells in the cerebrospinal fluid is determined on 1-2 day of a disease by an immunocytochemical method. In case the content of the CD31 is higher than 0.5% and the presence of S100 positive cells, an unfavourable course of bacterial purulent memingitis (BPM) is predicted. If the CD 31 content is lower than 0.5% and the absence of S100 positive cells, a favourable course of the disease is predicted.

Method of predicting post-operative regeneration in patients with false joints of long tubular bones

Invention describes a method of predicting post-operative regeneration in patients with false joints of long tubular bones, which includes analysis of the patient's venous blood, analysis of results of its analysis with formulation of a prediction of post-operative regeneration by selected parameters; in the patient's blood plasma determined are: a level of content of diene conjugates (DC) and double bonds (DB) in blood plasma lipids, quantity of lipids in the patient's blood plasma, quantity of "acute phase" protein -ceruloplasmin, as well as the percent content of highly stable erythrocytes in the patient's blood; integral indices of change of condition of molecular-biological processes in the equilibrium system of lipid peroxidation (LP) of the patient's blood plasma and its antioxidant protection (AOP). A product of content of diene conjugates (DC) and double bonds (DB) in the patient's blood plasma lipids is chosen as a criterion of development of a disbalance in the "LP-AOP" system of the patient's blood plasma, then, in case if the measured parameter of content of double bonds (DB) constitutes (29.6-37)10-7 M/mg of lipids, the measured parameter of content of diene conjugates (DK) constitutes (2.34-2.76)10-1 conventional units, calculated by the results of measurements integral index in the form of DB×DC product constitutes (69.3-102.1)10-8 conventional units, quantity of lipids in the patient's blood plasma constitutes 6.2-8.6 mg/ml, quantity of "acute phase" protein - ceruloplasmin in the patient's blood plasma constitutes 29.6-36.8 conventional units, and percent content of highly stable erythrocytes in the erythrocyte population in the patient's blood plasma constitutes (14.3-17.3)%, processes, accompanied by impairment of the structure of erythrocyte membranes with manifestation of retarded consolidation of an injured element of the musculoskeletal system with formation of a false joint, non-complicated by inflammatory processes, are predicted, and in case if the measured parameter of content of double bonds (DB) constitutes (41.6-49.4)10-7 M/mg of lipids, the measured parameter of content of diene conjugates (DC) constitutes (3.16-3.54)10-1 conventional units, calculated by the results of measurements integral index in the form of DB×DC product constitutes (131.5-174.9)10-8 conventional units, quantity of lipids in the patient's blood plasma constitutes 2.6-5.8 mg/ml, quantity of "acute phase" protein - ceruloplasmin in the patient's blood plasma constitutes 41.6-49.4 conventional units, and percent content of highly stable erythrocytes in the erythrocyte population in the patient's blood plasma constitutes (4.6-6.0)%, a process of impairment of the structure of erythrocyte membranes with manifestation of retarded consolidation of the injured element of the musculoskeletal system element with formation of a complicated with suppuration false joint is predicted.

Diagnostic technique for tuberculosis

Invention refers to medicine, particularly to medical diagnostics, and describes a diagnostic technique by immunohistochemical examination and detection of the Mycobacterium tuberculosis antigen expression. The method is characterised by examining a biological material applied on a slide by a modified immunohistochemical method and involves the following stages: preparing the biological material: smears/scrapes, packed cells of biological fluids to be fixed in acetone; preparing with 1% potassium bichromate; preparing with 3% hydrogen peroxide; applying monoclonal antibodies to Mycobacterium tuberculosis antigens dissolved 1:20; incubating at 3-5 degrees Celsius for 12 hours; applying EnVision detection system and incubating at room temperature; applying diaminobenzidine; counterstaining with haematoxyline; enclosing into a balm or other medium, microscopic examination, diagnosing the disease if observing the Mycobacterium tuberculosis antigen.

Method of detecting degenerative muscular diseases and method of determining therapeutic efficiency in case of diseases

Invention relates to a method of early detection of muscular degenerative diseases and to a method of prediction and/or determination of a therapeutic efficiency of a therapeutic preparation and/or a method of disease therapy by measurements of tetranor-PGDM (11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid) in a subject's urine sample and comparison of its content relative to a sample, separated from a healthy individual. A muscular degenerative disease is identified in a patient if the concentration or content of tetranor-PGDM in a sample, separated in the patient is higher than the concentration or content of tetranor-PGDM in a sample, separated from a healthy individual. An efficiency of the therapeutic preparation and/or the method of therapy of the muscular degenerative disease is determined by comparison of the content of tetranor-PGDM in the sample, separated from the patient with the muscular degenerative disease before and after introduction of the therapeutic preparation. If the measured content of tetranor-PGDM in the sample considerably or inconsiderably decreases after the introduction of the therapeutic preparation, the method of therapy is efficient. The invention also relates to a set for diagnostics of muscular degenerative diseases, which includes an antibody to tetranor-PGDM, labelled tetranor-PGDM and optionally, at least, one compound, selected from a group, consisting of an antibody to immunoglobulin, a diluting solution for the sample, a diluting solution for the antibody and labelled tetranor-PGDM, tetranor-PGDM standard of the known concentration, a substrate for an enzyme immunoassay and a stopping solution for the enzyme immunoassay.

Diagnostic technique for postvaccinal immunity to diphtheria in children living on territory of exposure to hazardous chemical factors

Invention involves the following stages: chemical environmental contaminants targeting the immune system on the territory of residence are listed. For the listed contaminants, a risk of immune disorders is assessed by a hazard index. If HI is more than 1.0, the children living in the specified conditions and vaccinated up to a schedule and/or re-vaccinated with a DPT vaccine - diphtheria and tetanus toxoids and pertussis vaccine - and suffering from no immune diseases are selected. Blood is sampled from the above children; the sample is examined to measure an amount of the specified chemical environmental contaminants to detect individuals with the above amount exceeding an ambient regional level by not less than 20%; an amount of postvaccinal immunoglobulin G (IgG) antibodies to diphtherial anatoxin is measured in the blood serum of the selected individuals by ELISA with specific test-systems. The individuals with the above amount being less than the protective level are selected and assigned with a correlation of the above antibodies from the blood concentration of the listed chemicals, and if stating the reliable relations simultaneously: high blood concentration of lead more than 0.04 mg/dm3 and of o-cresol more than 0 mg/dm3 and lower concentration of postvaccinal IgG antibodies to diphtherial anatoxin as compared to the protective level, a decrease of the postvaccinal immunity to diphtheria is diagnosed in the child.

Method for assessing sensitivity of vascular endothelium to shear stress

Method implies as follows: blood nitrites and endothelin are determined prior to and after an occlusion test. The sensitivity of the vascular endothelium to shear stress is determined by the coefficient index(e) calculated by formula. If the coefficient index(e) is 0.5 or less, the sensitivity of the vascular endothelium to shear stress is considered to be low, while the value index(e) of more than 0.5 shows the normal sensitivity value.

Diagnostic technique for early stage of rheumatoid arthritis

Bone marrow and synovium is sampled from a patient to produce preparations for immunohistological and immunocytochemical analyses. That is followed by determining a portion of Mdm2 protein synthesis cells by formula: A I M d m 2 = N M d m 2 ⋅ 100 N t o t a l , wherein AIMdm2 is a portion of Mdm2 protein synthesis cells, %; NMdm2 is a Mdm2 protein synthesis cell count; Ntotal is the total cell count in the range of vision. An early stage of rheumatoid arthritis is diagnosed if observing AIMdm2=81.6-88.8% in the patient's synovium, and AIMdm2=85.0-89.2% in the patient's bone marrow.

Cattle diarrhea virus with modified e^rns protein

Claimed invention relates to the field of biotechnology and virology. Described is a chimeric pestivirus, where the said chimeric pestivirus includes the cattle diarrhea virus, which does not express its homologous Erns protein. The said chimeric pestivirus expresses a heterologous Erns protein, originating from the other pestivirus, or a natural, synthetic or genetic version of the said heterologous Erns protein. Also described are methods and sets for treatment or prevention of propagation of the infection, caused by the cattle diarrhea virus, as well as methods for a differentiation between the vaccinated animals and the animals, infected with the virus of a wild type.

L-fucose α1→6 specific lectin

Group of inventions relates to biochemistry. Disclosed is L-fucose α1→6 specific lectin, which is extracted from a basidiomycete or an ascomycete or an ascomycete, characterised by peak molecular weight of about 4500 m/z, determined via MALDI-TOF mass spectrometry analysis. The novel L-fucose α1→6 specific lectin has high affinity for a L-fucose α1→6 sugar chain, represented by an association constant of 1.0×104 M-1 or higher (at 25°C), and has an association constant of 1.0×103 M-1 or lower (at 25°C) with high-mannose sugar chains and/or glucolipids which do not contain an L-fucose α1→6 sugar chain. In one version, the disclosed L-fucose α1→6 specific lectin is a protein or a peptide which consists of an amino acid sequence selected from SEQ ID NO:2-6. The L-fucose α1→6 specific lectin is used for specific detection of a L-fucose α1→6 sugar chain and effective purification of the L-fucose α1→6 sugar chain or a sugar chain which does not contain L-fucose α1→6.

Kit of reagents for simultaneous or separate immunohistochemical detection of oestrogen, progesterone and her2 receptors in diagnosing breast cancer

Kit of reagents contains a solution for providing an antigen bioavailability, a blocking solution of horseradish peroxidase, a protein blocking solution, a washing solution, a solution of primary HER2 receptor antibodies, a solution of primary oestrogen receptor antibodies, a solution of primary progesterone receptor antibodies, a solution of anti-species secondary antibodies to primary antibodies, a solution of streptavidin - horseradish peroxidase, diamine benzidine, a substrate solution, a negative reference sample, three positive reference samples of breast cancer for detecting HER2, oestrogen receptors, progesterone receptors. The kit of reagents according to the invention possesses higher sensitivity and specificity. The invention may be used in medical laboratories and research establishments.

Method of treating respiratory distress syndrome accompanying neonatal ventilation

Treating respiratory distress syndrome accompanying neonatal ventilation is ensured by measuring glutathione peroxidase (GSH-Px-3) with underlying drug therapy, and the measured value being less than 2.41 mcmole/l requires including intravenous bolus injections of the preparation Selenase in a therapeutic complex at 10 mcg/kg/day, once a day for 10 days.

Bone marrow technology from dead donors with beating and non-beating heart

Wings of ilium are punctured in an anterior and posterior one-third of the wings with two trocars being inserted into each wing. The bone marrow (BM) is collected by simple aspiration, aspiration irrigation or a combination thereof at an underpressure of 0.6 Atm with using a device. The bone marrow preparation device comprises a disposable multi-channel closed system, an aspiration collection unit and a perfusion unit. The group of inventions also refers to a method for assessing the prepared bone marrow. The effect is ensured by automatic control of myeloaspiration by preparing a biological material with using a special designed device for the bone marrow collection.

Method of assessment of disorder of cellular immunity in exposed to phenol

For evaluation of disorders of cellular immunity when exposed to phenol the blood sampling and its analysis is carried out using experimental and control samples with preliminary introduction to the test sample of toxicant - phenol in a concentration corresponding to its regional background level. As a criterion factors in the method the index of specific sensitivity of cells is used for cytokine tumour necrosis factor TNF-α and the index of specific sensitivity of cells to cytokine interleukin-10 IL-10, which are defined as follows: the experimental and control blood samples are placed into the vial with a sterile nutrient medium DMEM with heparin and gentamicin in a volume ratio of 1:4, respectively (in a preferred embodiment, the contents in the sterile nutrient medium DMEM of heparin is 2.5 U/ml and gentamicin - 100 mcg|ml), incubation of these samples is carried out at 37°C during 24 hours, followed by centrifugation for 3 minutes at 1000 rev/min, and in the selected supernatant of the test sample the level of IPCIL-10 phenol-induced production of cytokine IL-10 is determined and the level of IPCTNF-α phenol-induced production of cytokine - tumour necrosis factor TNF-α, and in the selected supernatant of the control sample the level of spontaneous cytokine production is determined, namely the SPCIL-10 level of spontaneous production of cytokine IL-10 and SPCTNF-α level of spontaneous production of the cytokine TNF-α, then ISSTNF-α index of specific sensitivity of cells for cytokine TNF-α is calculated, and the ISSIL-10 index of specific sensitivity of cells for cytokine IL-10 is calculated using the following formulas: ISSTNF-α=(IPCTNF-α- SPCTNF-α): SPCTNF-α, ISSIL-10 =(IPCIL-10- SPCIL-10): SPCIL-10, where IPCIL-10 is the level of phenol-induced production of cytokine IL-10; IPCTNF-α is the level of phenol-induced production of cytokine TNF-α; SPCIL-10 is the level of spontaneous production of cytokine IL-10; SPCTNF-α is the level of spontaneous production of the cytokine TNF-α; and when meeting the simultaneous requirement of ISSTNF-α of over 10 and ISSIL-10 of over 2 the disorder of cellular immunity of the organism is determined under the influence of phenol.

Diagnostic technique for rheumatoid arthritis if mutated citrullinated vimentin antibodies (anti-mcv) are found in oral fluid

Diagnostic technique according to the present invention consists in measuring Anti-MCV in the oral fluid (mixed saliva), using mathematical expression F=0.17×Anti-MCV-0.2537 for processing derived values Anti-MCV in the oral fluid, diagnosing rheumatoid arthritis if observing F more than zero, and stating a doubtful diagnosis of rheumatoid arthritis if deriving negative F values.

Method for prediction of onset of pregnancy in females with tubal-peritoneal infertility in in vitro fertilisation programme

In vitro fertilisation (IVF) programme is preceded by luteal-phase endometrial biopsy to determine a relative CD95+ macrophage count in an endometrial leukocytic infiltrate. If the relative CD95+ macrophage count is 48.8% or more, the onset of pregnancy is predicted, while the value being less than 48.8% shows the absence of the onset of pregnancy. The declared method extends the range of prognostic aids, increases the accuracy, sensitivity and specificity of the prediction procedure for the onset of pregnancy in the females suffering from tubal-peritoneal infertility prior to IVF programme.

Test strip for highly sensitive immunochromatographic analysis

Method is based on a contact of a membrane test strip with an analysed liquid sample and initiated by the said contact movement on the test strip membranes of reagents, contained in the sample or applied on the membrane and forming immune complexes in membrane pores or its surface in the course of interactions. Intensity of coloration of a mark, which binds in an analytic zone, is detected visually. The claimed system is intended for immunochromatographic determination of antibodies or antigens in liquid samples. A characteristic feature of the claimed method of carrying out an immunochromatographic analysis consists in the following: a multimembrane composite of the test strip contains an additional membrane with a substance applied on it substance, which dissolves in water slowly, for instance a bovine serum albumin (BSA), which is attached to the test strip immediately after the membrane with the applied colloid conjugate. The front of the liquid sample, passing the membrane with colloidal gold, conjugated with a reagent for analite binding, stops, after getting on the membrane with BSA, until BSA is dissolved. During this time the sample is incubated with the colloidal conjugate, which approaches a reaction of analite binding to an equilibrium position.

Single-domain mini-antibody aher2/askbr3-1, specifically binding epidermal growth factor receptor her2/erbb2/neu and capable to penetrate through this interaction into target cells (internalised), method of production of this antibody and method of detection of protein her2/erbb2/neu and cells expressing this protein in increased amount, using mini-antibody aher2/askbr3-1

Single-domain mini-antibody is proposed, specifically binding the protein-receptor of epidermal growth factor of human HER2/ERBB2/neu obtained by immunisation of two-humped camel (Camelus bactrianus) by the preparation of tumour cells SKBR3, and characterised by the amino acid sequence. Also the method of detecting protein HER2/ERBB2/neu and its expressing cells is considered. The antibody according to the present invention is able to penetrate in the target cell on which surface HER2/ERBB2/neu is exposed, and may find further application in diagnostics and therapy of diseases associated with overexpression of HER2/ERBB2/neu.

Integrated method for detecting circulating tumour cells in blood of patients suffering from breast cancer

Method describes determining circulating tumour cells sensitive to adjuvant hormone therapy in blood of patients suffering from breast cancer, and involves recovering and enriching the circulating tumour cells with using magnetically marked antibodies, producing lysates of the circulating tumour cells, recovering iRNA from the lysates of the circulating tumour cells, producing cDNA, producing amplified DNA, determining expression of marker genes; if observing one of the markers GA733-2, MUC-1, HER2, the presence of the circulating tumour cells is stated; and if the markers ESR1, PGR are present, the circulating tumour cells sensitive to hormone therapy is concluded.

Method for assessing risk of developing cervical cancer formation in females with human papillomavirus infection

Cervical biopsy material tissues taken by colposcopic biopsy are examined for typing a human papillomavirus (HPV), apoptosis values (sFAS, TRAIL), genetic characteristics of expression of the genes regulating apoptosis processes, as well as radical formation processes (pyeloperoxidase activity, nitrate-nitrite levels, total antioxidant tissue capacity by the Fenton-type reaction). A summing risk factor of developing cervical cancer formation is calculated by formula. If the summing risk factor K is less than 3, then a low risk of cancer formation is predicted; if K is 3 or more, the risk of cancer formation is considered to be high.

Method for typing tissue-specific transcription factor hnf4α isoforms in human hepatocellular carcinomas

Invention refers to medicine and concerns a method for typing tissue-specific transcription factor HNF4α isoforms in human hepatocellular carcinomas. The method represents an immune histochemical study with using monoclonal antibodies to HNF4α isoform types and is characterised by the fact that for detecting antigens a two-stage high-sensitive polymeric peroxidase system is used. A retrieval procedure is performed in a citrate buffer at pH 6.0 and t=95°; an incubation with primary antibodies uses a high dilution of HNF4αP2 and HNF4αP1 antibodies - 1.5 mcg/ml and 3 mcg/ml respectively.

Method for prediction of efficacy of antiviral therapy in adult patients with chronic hepatitis c genotype 1b

Lymphocyte subpopulation fractions are measured, and a predictive index is calculated with calculating a lymphocyte subpopulation percentage by flow cytofluorometry. If the predictive index PI<350, achieving the fast virological response to antiviral therapy of CHC is predicted; if the predictive index PI>350, the absence of the fast virological response to antiviral therapy of chronic hepatitis C genotype 1b is predicted.

Method for prediction of aggravated bronchial asthma and/or cystic fibrosis accompanying influenza in children

Prognostic indices resulted from calculated interleukins IL-4, IL-10 and interferon gamma IFN-y in blood serum are determined by enzyme immunoassay on the first and third day of the disease. An increase of interleukin IL-4, IL-10 and a decrease of IFN-γ over time with an increase of the relations of IL-4/IFN-γ by the third day at least in 5-6 times, and of IL-10/IFN-γ at least in 4-5 times, influenza can be considered as a trigger of aggravated chronic bronchopulmonary pathology - bronchial asthma and cystic fibrosis. The derived coefficients determine an algorithm of early application of combined therapeutic schemes of influenza in the children with chronic non-specific pulmonary diseases with using antiviral, antibacterial and immunocorrecting preparations for the purpose of eliminating cytokine imbalance and preventing virus-induced bronchial obstruction as a result of less hyperactive tracheobronchial tree. A prognostic accuracy of the presented method makes 85-90%.

Diagnostic technique for nephrotic syndrome with minimal changes in children

Method involves assessing biologically significant values in the children with primary nephrotic syndrome with intact renal function; that is ensured by measuring urine IL-18 by solid-phase enzyme-linked immunosorbent assay. If the derived value falls within the range of 74.7 to 540 pg per 1 mg of creatinine, nephrotic syndrome with minimal changes in the children is diagnosed.

Method of diagnosing oncological diseases and immunoassay set for its realisation

Group of inventions relates to the field of medical diagnostics, immunology and oncology, in particular to novel oncomarkers and methods of diagnosing oncologic diseases. Claimed are novel antigens for carrying out immunoassay in order to identify autoantibodies, associated with malignant neoplasms, namely fragments of kringle-containing plasminogen. Also claimed is a method of identification of a diagnostic feature in case of oncologic diseases, consisting in identification of IgA, IgG, IgM type of autoantibodies to the following fragments of plasminogen: heavy chain (Glu-H), heavy chain (Lys-H), light chain (L), K1-4 (Tyr80-Ala440), K1-3 (Tyr80-Val338), K1-3 (Tyr80-Val354), K1-4 (Asn60-Pro447), K1-4 (Lys78-Pro447), K1-4 (Lys78-Pro446), K1-4 (Lys78-Lys468), K1-4.5 (Lys78-Arg530), K4-5 (Val355-Phe546), K1 (Tyr80-Glul64), K2-3 (Cysl65-Val338), K4 (Val354-Ala440), K5 (Ser441-Fhe546), K5 (Val442-Arg561), miniplasmin in a human blood plasma sample.

Diagnostic technique for benign and malignant osseous growths

Enzyme immunoassay is used to measure blood serum neopterin NP, vascular cellular adhesion molecules vCAM, intracellular cell adhesion molecules ICAM, tumour necrosis factor TNF-α, interleukin-6 IL-6. The coefficient K is calculated by formula: K = N P + v C A M I C A M + T N F − α I L − 6 . If K≤12.5, a benign process is diagnosed, while K>12.5 shows a malignant process.

Method of human protein cxcl1 immunoassay

Invention relates to biochemistry. A method of immunoassay of human protein CXCL1 is described. Human CXCL1 or its fragment is measured in a sample with application of two or more types of monoclonal antibodies to human CXCL1 or their fragments. Each of two or more types of the monoclonal antibodies to human CXCL1 or their fragments specifically identifies any of regions of a sequence of amino acid sequences, represented in SEQ ID NO:1-3, which represent partial sequences of an amino acid sequence, constituting human protein CXCL1. Two or more types of the monoclonal antibodies to human CXCL1 or their fragments specifically identify regions of the sequence, different from each other. Claimed are the monoclonal antibodies or their fragments, each of which specifically identifies any region of the amino acid sequence, represented in SEQ ID NO:1-3, and has a new amino acid sequence.

Method for prediction of developing infectious syndrome in patients with acute leukemia

To predict developing infectious syndrome in patients with acute leukemia, CD16+ neutrophil count is determined in a patient's bone marrow. If bone marrow CD16+ neutrophil count is less than 50%, developing infectious syndrome with clinical manifestations is predicted.

Method for prediction of developing placental insufficiency

Invention refers to medicine, namely to laboratory diagnostics and concerns a method for early prediction of developing placental insufficiency. The method involves: measuring early blood serum interleukin 6 (IL-6), interleukin 8 (IL-8), a soluble vascular cellular adhesion molecule (sVCAM), a vascular endothelial growth factor (VEGF) and big-endothelin. Then, a prognostic index (PI) is calculated by formula: PI=0.63697X1-0.02367X2+0.00235X3-0.03931X4-15.99295X5-2.11547, wherein X1 is the IL-6 concentration, pg/ml; X2 is the IL-8 concentration, pg/ml; X3 is the sVCAM concentration, ng/ml; X4 is the VEGF concentration, pg/ml; X5 is the big-endothelin concentration, fmol/ml. If PI>0, developing placental insufficiency is predicted in the second half of pregnancy, while PI<0 enables stating a low risk of developing pathology specified above. The presented method is low-invasive, enables early detecting a risk group of developing placental insufficiency that makes it possible to take measures aiming at preventing the formation of the given pathology. Sensitivity of the method makes 77.4%, its specificity makes - 85.6%.

Early diagnostic technique for autoimmune oophoritis in adolescent girls suffering from normogonadotropic hypoovarianism

Blood serum neopterin is measured in adolescent girls suffering FROM normogonadotropic hypoovarianism and unspecified oligomenorrhea by immunofluorescent assay. If serum neopterin is 9.86 nmole/l or more, autoimmune oophoritis is diagnosed.